Quantitatively measuring the degree of concordance between or among microarray probe level data sets
WO2009086532A1
Neurite outgrowth as an assay for memory enhancing compounds
CN101820764A
Therapeutic isoxazole compounds
BRPI0815694A2
COMPOUNDS, PHARMACEUTICAL COMPOSITION, USES OF PHARMACEUTICALLY ACCEPTABLE COMPOUNTS OR SALTS OR PRODUCT ESTERS OR COMPOSITIONS OF THE SAME AND PHARMACEUTICALLY ACCEPTABLE SALTS METHODS OF PREPARATION OF ORGANIZATION OF THE DETERMINATION OF ORGANIZATION OF ORGANIZATION MEMORY, Mild COGNITIVE DETERIORATION, ALZHEIMER DISEASE OR ALZHEIMER DISEASE OR PARKINSON DISEASE ASSOCIATED WITH PSYCHIATRIC DISORDER TREATMENT AND TREATMENT OF MEMORY DETERIORATION IN ONE ANIMAL.
AU2008261803A1
Therapeutic pyrazolonaphthyridine derivatives
AU2008261888A1
Therapeutic pyrazoloquinoline urea derivatives
BRPI0812366A2
compound, pharmaceutical composition and methods of modulating one or more gabaa subtypes, treating cognitive dysfunction and psychiatric disorder and increasing cognitive function in animals and uses of the compound or composition.
CA2684920A1
Methods of treating cognitive disorders by inhibition of gpr12
BRPI0811623A2
Methods for identifying genes involved in memory formation using small interferent rna (sirna)
BRPI0712938A2
Method for modulating neurite outgrowth by use of a galanin-3 receptor antagonist
EP2377533A2
Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
CN101490017A
Therapeutic piperazines as pde4 inhibitors
US2007135510A1
Indolone compounds useful to treat cognitive impairment
SK500262008A3
Use of indolone compounds for the manufacture of a medicament for the treatment of cognitive impairment
